- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
NovelStem Announces Material Developments and Strategic Repositioning of the Company Boca Raton, FL, May 20, 2025 – NovelStem...
Arbitration Confirms NovelStem Joint Venture’s Rights to Exploit ‘Tom Clancy’s Net Force’ Franchise Globally via Film, TV, Online,...
NovelStem, Focused on a Patented Genetic Platform Technology for Anti-Cancer Therapies, Reports First Quarter Results on Form 10-Q Boca...
NovelStem’s Affiliate NewStem Announced New Collaboration to Validate its Software Diagnostic Device for Two Oncology Indications and Two...
NovelStem Reports Third Quarter Results on Form 10-Q Boca Raton, FL, November 14, 2022 – NovelStem International Corp. (OTC Pink: NSTM),...
NovelStem Now an SEC-Reporting Company, Secures Commitment for up to $600K in Bridge Funding, Provides Financial Update Boca Raton, FL,...
NewStem is the only company worldwide to develop therapeutics and diagnostics products based on haploid human embryonic stem cell...
NovelStem Reviews Efforts to Maximize Value from Legacy Entertainment Asset Boca Raton, FL, February 15, 2022 – NovelStem International...
NovelStem Files Preliminary Financial Statements in Compliance with SEC Rule 15c2-11, Enabling its Common Stock to Advance to the OTC...
NovelStem Announces NewStem, Ltd. was Selected by Illumina for its Global Illumina Accelerator Boca Raton, FL & Jerusalem, Israel,...